Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 848-854

  Miyake, Naomi ^a   Chikumi, Hiroki ^a   Takata, Miyako ^a   Nakamoto, Masaki ^a   Igishi, Tadashi ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bcl 2; Cytochrome c; Non small cell lung cancer; Rapamycin

Indexed keywords

CASPASE 3; CYTOCHROME C; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN P53; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE MUTATION; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; MUTATION; SIROLIMUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865325644     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1855     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Delbaldo C, Michiels S, Rolland E, et al: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 17: CD004569, 2007.
3. Hanahan D: The hallmarks of cancer. Cell 100: 57-70, 2000.
4. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
5. Shaw RJ and Cantley LC: Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
6. LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50, 2008.
7. Sabers CJ, Martin MM, Brunn GJ, et al: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270: 815-822, 1995.
8. Lorenz MC and Heitman J: TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 270: 27531-27537, 1995.
9. Balsara BR, Pei J, Mitsuuchi Y, et al: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.
10. Wislez M, Spencer ML, Izzo JG, et al: Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65: 3226-3235, 2005.
11. Marinov M, Fischer B and Arcaro A: Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63: 172-182, 2007.
12. Gridelli C, Maione P and Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13: 139-147, 2008.
13. Muthukkumar S, RaMesh TM and Bondada S: Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60: 264-270, 1995.
14. Tirado OM, Mateo-Lozano S and Notario V: Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 24: 3348-3357, 2005.
15. Zhang JF, Liu JJ, Lu MQ, et al: Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 17: 162-168, 2007.
16. Vega F, Medeiros LJ, Leventaki V, et al: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66: 6589-6597, 2006.
17. Aguirre D, Boya P, Bellet D, et al: Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9: 797-805, 2004.
18. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T and Houghton PJ: p53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res 61: 3373-3381, 2001.
19. Huang S, Shu L, Easton J, et al: Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 279: 36490-36496, 2004.
20. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G and Nicolin A: Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 37: 2121-2128, 2001.
21. Boffa DJ, Luan F, Thomas D, et al: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10: 293-300, 2004.
22. Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006.
23. Kishimoto M, Kohno T, Okudela K, et al: Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 11: 512-519, 2005.
24. Okabe T, Okamoto I, Tamura K, et al: Differential constitutive activation of the epidermal growthfactor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67: 2046-2053, 2007.
25. Mori T, Okamoto H, Takahashi N, Ueda R and Okamoto T: Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 465: 124-128, 2000.
26. Park MJ, Shimizu K, Nakano T, et al: Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet 141: 5-13, 2003.
27. Nagai Y and Miyazawa H: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
28. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
29. del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689, 1997.
30. Gardai SJ, Hildeman DA, Frankel SK, et al: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279: 21085-21095, 2004.
31. Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
32. Migita K, Eguchi K, Ichinose Y, et al: Effects of rapamycin on apoptosis of rheumatoid synovial cells. Clin Exp Immunol 108: 199-203, 1997.
33. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
34. Zhang YJ, Duan Y and Zheng XF: Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 16: 325-331, 2011.
35. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030, 2008.